GLTO vs. FLGC, BIVI, KALA, NRBO, GLYC, NNVC, APM, ORGS, TCRT, and MEIP
Should you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Flora Growth (FLGC), BioVie (BIVI), KALA BIO (KALA), NeuroBo Pharmaceuticals (NRBO), GlycoMimetics (GLYC), NanoViricides (NNVC), Aptorum Group (APM), Orgenesis (ORGS), Alaunos Therapeutics (TCRT), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical preparations" industry.
Galecto (NASDAQ:GLTO) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
In the previous week, Galecto and Galecto both had 1 articles in the media. Galecto's average media sentiment score of 0.67 beat Flora Growth's score of -1.00 indicating that Galecto is being referred to more favorably in the media.
14.2% of Galecto shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 12.1% of Galecto shares are owned by insiders. Comparatively, 17.6% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Galecto has a net margin of 0.00% compared to Flora Growth's net margin of -75.33%. Flora Growth's return on equity of -60.26% beat Galecto's return on equity.
Galecto currently has a consensus price target of $5.33, suggesting a potential upside of 661.80%. Flora Growth has a consensus price target of $7.00, suggesting a potential upside of 379.45%. Given Galecto's higher probable upside, research analysts clearly believe Galecto is more favorable than Flora Growth.
Galecto has higher earnings, but lower revenue than Flora Growth. Galecto is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Galecto has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.
Galecto received 17 more outperform votes than Flora Growth when rated by MarketBeat users. However, 59.09% of users gave Flora Growth an outperform vote while only 58.82% of users gave Galecto an outperform vote.
Summary
Flora Growth beats Galecto on 9 of the 15 factors compared between the two stocks.
Get Galecto News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
